Efficacy of piperacillin-tazobactam in the treatment of febrile neutropenic patients with malignant hematopoietic disorders

Abstract

Objective To evaluate the effect and safety of piperacillin-tazobactam on febrile neutropenic patients with hematological malignancy. Methods A total of 34 patients received piperacillin-tazobactam 4.5 g every 8 hours and 52 cases received meiluopeinan 0.5 g every 6 hours. Etimicin was combined in both groups. Results Clinical responses between groups were comparable. The effective rate of piperacillin-tazobactam and meiluopeinan were 73.53% and 80.77% respectively (P＞0.05), the side effects were mild in both groups, but the superinfection was more common in meiluopeinan group (15.38%) than that in piperacillin-tazobactam (5.88%, P＞0.05). Conclusions Piperacillin-tazobactam is as effective as meiluopeinan with fewer superinfection. It seems to be a good choice as initial empiric therapy for febrile neutropenic patients with malignant hematological diseases. Key words: Piperacillin-tazobactam; Meiluopeinan; Febrile neutropenia; Hematological malignancy